Biomedical Research

VHB plays an important role in delivering mission critical certainty for biopharmaceutical firms, institutions, and life sciences firms needing to build, upgrade, or expand. It’s no wonder that world class corporations like Bristol Myers Squibb and Pfizer look to VHB to bring their local knowledge, technical expertise, and quality assurance to help them move their project from site selection to commissioning to market, on time, on budget, and within compliance. We get results because we understand that these facilities must be designed with utmost flexibility, be scalable, and be up and running quickly since every second gained is a competitive advantage and possibly worth millions. Armed with years of experience and a thirst to outperform, you can count on VHB to bring certainty to the mission-critical process.

Mark Junghans is a Managing Director of Land Development at VHB.

Mark Junghans

Managing Director, Land Development


  • Alexandria Real Estate Equities

  • Altria Group

  • Amgen, Inc.

  • Arranta Bio

  • AstraZeneca Pharmaceuticals LP

  • BioMed Realty Trust, Inc.

  • Biogen

  • Boehringer Ingelheim Pharmaceuticals

  • Boston Properties, Inc.

  • Boston Scientific Corporation

  • Bristol Myers Squibb Company

  • Broad Institute

  • Dana Farber Cancer Institute

  • Fluor Enterprises, Inc

  • Genetics Institute

  • IQHQ Properties

  • LifeNet

  • MIT Lincoln Lab

  • Novartis Institute for Biomedical Research

  • Partners HealthCare

  • Pfizer

  • Sanofi Genzyme

  • The Broad Institute​

  • Vertex Pharmaceuticals, Inc.